Insmed (INSM) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of its DPP1 inhibitor BRINSUPRI for the treatment of non-cystic fibrosis bronchiectasis in patients 12 years of age and older with two or more exacerbations in the prior 12 months. If approved, BRINSUPRI would be first-in-class and the first approved therapy in the European Union to treat NCFB.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed price target raised to $194 from $140 at UBS
- Insmed’s Promising Growth Prospects: Buy Rating Driven by Brinsupri’s Blockbuster Potential and Strategic Market Positioning
- Private Markets: AI model startup Reflection AI raises $2B
- Insmed price target raised to $193 from $154 at TD Cowen
- Insmed’s TPIP Shows Promising Phase 2 Results, Boosting Buy Rating and Future Prospects